In short
Clinical trials investigating Saxagliptin are studying it in people with heart failure with reduced ejection fraction and adults with type 2 diabetes. These trials look at safety, treatment effects, and changes in key health measures such as heart failure events and HbA1c, a blood sugar marker.
Key points
- Clinical trials investigating Saxagliptin in the source data involve heart failure with reduced ejection fraction and type 2 diabetes. One completed study looked at treatment initiation strategies in heart failure, while another authorised Phase 3 study in adults with type 2 diabetes measured change in HbA1c. The heart failure trial used a composite outcome that included blood pressure, kidney, hospital, and death-related events. Saxagliptin appears in these trials as part of treatment groups, not as the main focus of the research. Overall, the data show Saxagliptin being studied in adult patient groups with common long-term conditions.
Trial overview
The source data include two clinical trials that mention Saxagliptin as part of the study treatment options. One trial studied people with heart failure with reduced ejection fraction, and the other studied adults with type 2 diabetes. These are interventional studies, which means the researchers assigned treatments and then measured results.
Heart failure study
NCT05989503 was a completed randomized open-label trial in patients with heart failure with reduced ejection fraction. It enrolled 172 people and was designed to compare two ways of starting treatment: giving angiotensin receptor-neprilysin inhibitor and SGLT2 inhibitor together, or starting SGLT2 inhibitor first and adding the other treatment later. Saxagliptin appeared in one of the listed drug combinations in the study data.
The study asked whether the safety of starting the two heart failure treatments at the same time was not worse than the step-by-step approach. “Not worse than” is called non-inferior, which means the new approach is expected to perform at least as well as the comparison approach within a set margin.
Type 2 diabetes study
NCT05433584 is an authorised Phase 3 study in adult participants with type 2 diabetes. It enrolled 781 participants and compared tirzepatide with intensified conventional care. Saxagliptin was one of the diabetes medicines listed in the intervention set for this trial.
The main goal was to show that tirzepatide was not worse than intensified conventional care for change in HbA1c from baseline to Week 104. HbA1c is a blood test that reflects average blood sugar over time, so it is a key measure in diabetes studies.
Outcomes measured in the trials
The heart failure trial used a composite outcome, which combines several events into one main result. These events included symptomatic hypotension, hyperkalaemia, hypokalemia, a major drop in eGFR, kidney failure outcomes, increased diuretic dose, intravenous diuretics, heart failure hospitalization, and death from cardiovascular causes during 6 months of follow-up.
The diabetes trial focused on change in hemoglobin A1c (HbA1c) from the start of the study to Week 104. This outcome helps show whether a treatment strategy improves long-term blood sugar control.
Who was studied
The heart failure study involved patients with heart failure with reduced ejection fraction, and the study summary also mentioned HFmrEF, which means heart failure with mildly reduced ejection fraction. The diabetes study involved adult participants with type 2 diabetes. In both trials, Saxagliptin was part of the study drug list rather than the only treatment being tested.
What these trials show about Saxagliptin research
Based on the source data, Saxagliptin is being studied in different clinical settings, including heart failure research and diabetes research. The trials focus on practical patient outcomes such as safety events, kidney changes, hospitalisation, death from cardiovascular causes, and HbA1c change. This means the research is aimed at understanding how treatment strategies perform in real patient groups with chronic disease.